LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo

    Liu, Weiwei / Shang, Jingyu / Deng, Yinxiang / Han, Xiuzhen / Chen, Yugen / Wang, Shuangshuang / Yang, Ruwen / Dong, Fan / Shang, Hongtao

    Journal of ethnopharmacology. 2022 Sept. 15, v. 295

    2022  

    Abstract: Jian Pi Qing Gan Yin (JPQGY) has been used clinically to relieve non-alcoholic fatty liver disease (NAFLD) in China for decades; however, the underlying mechanisms of JPQGY remain unclear. We evaluated the effects and mechanisms of JPQGY and hepatic ... ...

    Abstract Jian Pi Qing Gan Yin (JPQGY) has been used clinically to relieve non-alcoholic fatty liver disease (NAFLD) in China for decades; however, the underlying mechanisms of JPQGY remain unclear. We evaluated the effects and mechanisms of JPQGY and hepatic steatosis caused by the middle stage of 13-week-high-fat-diet-induced NAFLD in mice. Different dosages of JPQGY (5.5, 11, and 22 g/kg/day) were administered to NAFLD mice simultaneously. Body weight, body mass index (BMI), and liver lipid- and inflammation-related serum indicators were measured enzymatically. Liver samples were stained with Oil Red O and hematoxylin and eosin (H&E). Next, we performed a network pharmacology analysis and verified eight target genes mapping to NAFLD-related lipid metabolism pathways. The mRNA/protein expression was analyzed by real-time polymerase chain reaction (PCR) and western blotting. JPQGY significantly relieved histological damage (steatosis-inflammation-fibrosis), prevented the downregulation of AMPK and Pparα, and upregulated LXRα, Srebp-1c, F4/80, Nf-κb, and Cyp2e1 in the HFD-induced NAFLD mouse model. The present results suggest that chronic treatment with JPQGY ameliorated HFD-induced NAFLD in mice by targeting the first and second phases of hepatic steatosis by stimulating the AMPK/PPARα pathway and inhibiting the LXRα/Srebp1/Nf-κb pathway. Our findings provide evidence that supports the clinical use of this formula for high-fat diet-induced fatty liver disease.
    Keywords blood serum ; body weight ; eosin ; fatty liver ; high fat diet ; histology ; lipid metabolism ; liver ; mice ; pharmacology ; protein synthesis ; quantitative polymerase chain reaction ; traditional medicine
    Language English
    Dates of publication 2022-0915
    Publishing place Elsevier B.V.
    Document type Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2022.115382
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo.

    Liu, Weiwei / Shang, Jingyu / Deng, Yinxiang / Han, Xiuzhen / Chen, Yugen / Wang, Shuangshuang / Yang, Ruwen / Dong, Fan / Shang, Hongtao

    Journal of ethnopharmacology

    2022  Volume 295, Page(s) 115382

    Abstract: Ethnopharmacological relevance: Jian Pi Qing Gan Yin (JPQGY) has been used clinically to relieve non-alcoholic fatty liver disease (NAFLD) in China for decades; however, the underlying mechanisms of JPQGY remain unclear.: Aim of the study: We ... ...

    Abstract Ethnopharmacological relevance: Jian Pi Qing Gan Yin (JPQGY) has been used clinically to relieve non-alcoholic fatty liver disease (NAFLD) in China for decades; however, the underlying mechanisms of JPQGY remain unclear.
    Aim of the study: We evaluated the effects and mechanisms of JPQGY and hepatic steatosis caused by the middle stage of 13-week-high-fat-diet-induced NAFLD in mice.
    Materials and methods: Different dosages of JPQGY (5.5, 11, and 22 g/kg/day) were administered to NAFLD mice simultaneously. Body weight, body mass index (BMI), and liver lipid- and inflammation-related serum indicators were measured enzymatically. Liver samples were stained with Oil Red O and hematoxylin and eosin (H&E). Next, we performed a network pharmacology analysis and verified eight target genes mapping to NAFLD-related lipid metabolism pathways. The mRNA/protein expression was analyzed by real-time polymerase chain reaction (PCR) and western blotting.
    Results: JPQGY significantly relieved histological damage (steatosis-inflammation-fibrosis), prevented the downregulation of AMPK and Pparα, and upregulated LXRα, Srebp-1c, F4/80, Nf-κb, and Cyp2e1 in the HFD-induced NAFLD mouse model.
    Conclusions: The present results suggest that chronic treatment with JPQGY ameliorated HFD-induced NAFLD in mice by targeting the first and second phases of hepatic steatosis by stimulating the AMPK/PPARα pathway and inhibiting the LXRα/Srebp1/Nf-κb pathway. Our findings provide evidence that supports the clinical use of this formula for high-fat diet-induced fatty liver disease.
    MeSH term(s) AMP-Activated Protein Kinases/metabolism ; Animals ; Diet, High-Fat ; Inflammation/pathology ; Lipid Metabolism ; Liver ; Mice ; Mice, Inbred C57BL ; NF-kappa B/metabolism ; Network Pharmacology ; Non-alcoholic Fatty Liver Disease/metabolism ; PPAR alpha/genetics ; PPAR alpha/metabolism
    Chemical Substances NF-kappa B ; PPAR alpha ; AMP-Activated Protein Kinases (EC 2.7.11.31)
    Language English
    Publishing date 2022-05-14
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2022.115382
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top